Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway.

Pharmacological research - 1 Mar 2024

Shi Chen, Wang Cong, Fu Zhiwen, Liu Jinmei, Zhou Yuanfeng, Cheng Bao, Zhang Cong, Li Shijun, Zhang Yu

Abstract excerpt

Almonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC). However, the development of resistance inevitably occurs and poses a major obstacle to the clinical efficacy of almonertinib. Therefore, a clear understanding of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endopeptidases

Share to Indoles

Share to Lipocalin-2

Share to Matrix Metalloproteinase 9

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 38295916
DOI: 10.1016/j.phrs.2024.107088

Genes

LCN2
EGFR
AR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway.PMID 38295916Read ↗

Oncogenic and tumor-suppressive roles of Lipocalin 2 (LCN2) in tumor progressionSemantic proximity Read ↗

Lipocalin-2 Inhibits Osteosarcoma Cell Metastasis by Suppressing MET Expression via the MEK–ERK PathwaySemantic proximity Read ↗

Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses.Semantic proximity Read ↗

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cellsSemantic proximity Read ↗

<i>In vitro</i> and <i>in vivo</i> evidences propound therapeutic potential of Lipocalin 2 in cervical carcinomaSemantic proximity Read ↗

TGM2-TUFM promotes acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC through p62-mediated lipophagy.Semantic proximity Read ↗

LCN2: Versatile players in breast cancerSemantic proximity Read ↗

Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer typesSemantic proximity Read ↗

LMNA Reduced Acquired Resistance to Erlotinib in NSCLC by Reversing the Epithelial-Mesenchymal Transition via the FGFR/MAPK/c-fos Signaling Pathway.Semantic proximity Read ↗

Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transitionSemantic proximity Read ↗

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers.Semantic proximity Read ↗

Lipocalin 2 promotes breast cancer progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.